Mesalamine 1000 mg ER Four Times Daily for Maintenance of Remission in Ulcerative Colitis
For an adult in remission from ulcerative colitis, mesalamine 1000 mg ER four times daily (total 4 grams/day) is an appropriate and effective maintenance regimen, though once-daily dosing of the same total dose should be preferred for improved convenience without compromising efficacy.
Recommended Dosing Strategy
Total Daily Dose
- Mesalamine 2.4 grams/day is the standard maintenance dose for adults in remission from ulcerative colitis 1
- Higher doses up to 4.8 grams/day are also effective and FDA-approved for maintenance therapy 2
- Your current regimen of 4 grams/day (1000 mg × 4) falls within the effective therapeutic range 2, 3
Dosing Frequency Optimization
- Once-daily dosing is preferred over multiple daily doses when using oral mesalamine for maintenance therapy 1
- The AGA conditionally recommends once-daily dosing rather than multiple times per day dosing based on moderate quality evidence 1
- Consider switching to 4 grams once daily rather than 1 gram four times daily, as this provides equivalent efficacy with improved convenience 4
- Meta-analysis demonstrates no difference in clinical remission rates (RR 0.95; 95% CI 0.82-1.10) or relapse rates at 6 months (RR 1.10; 95% CI 0.83-1.46) or 12 months (RR 0.92; 95% CI 0.83-1.03) between once-daily and conventional dosing 4
Evidence Supporting Your Current Dose
Efficacy Data
- FDA trials demonstrate 84% of patients maintained remission at 6 months using mesalamine 2.4 grams once daily 2
- Higher dose mesalamine (4 grams/day) achieved 64% remission rates at 12 months compared to 38% with placebo (P = 0.0004) in controlled trials 3
- Both 2.4 g/day and 4.8 g/day dosages demonstrated similar efficacy profiles for induction and maintenance 2
Safety Profile
- Mesalamine is well-tolerated with rare serious adverse events across all dosing regimens 1, 5
- Treatment-related adverse events were rare even at 4 grams/day in long-term studies 3
- Mesalamine is safe for prolonged maintenance therapy and carries chemoprotective benefits 6, 5
Clinical Considerations
When Higher Doses Are Indicated
- Patients with left-sided or extensive disease may benefit from higher mesalamine doses (>3 grams/day) 1
- Adding rectal mesalamine to oral therapy should be considered for patients with extensive or left-sided disease 1
- Patients who relapsed on lower maintenance doses (1.5-2.25 g/day) showed 66% clinical improvement when escalated to 4 grams/day 7
Monitoring and Adherence
- Nonadherence is common with mesalamine therapy despite its safety profile 5
- Once-daily dosing may improve adherence in real-world settings, though clinical trials have not consistently demonstrated this benefit 4
- Continue the medication that successfully induced remission for maintenance therapy unless contraindicated 1
Key Pitfalls to Avoid
- Do not use four-times-daily dosing when once-daily is equally effective – this unnecessarily complicates the regimen and may reduce adherence 1, 4
- Do not reduce the dose below 2.4 grams/day for maintenance without clinical justification, as this is the minimum standard dose 1
- Do not discontinue mesalamine prematurely – it should be continued long-term for maintenance of remission 1, 3
- Monitor renal function periodically as the kidney is the major target organ of mesalamine toxicity in animal studies, though serious renal effects are rare in humans 2
Bottom Line
Your current total daily dose of 4 grams is appropriate and evidence-based for maintenance of remission in ulcerative colitis 2, 3. However, consolidating this to once-daily administration (4 grams once daily) rather than four divided doses would align with current guideline recommendations and potentially improve adherence without compromising efficacy 1, 4.